Mauskopf J, Earnshaw S. A methodological review of US budget-impact models for new drugs. Pharmacoeconomics. 2016 Nov;34(11):1111-31. doi: 10.1007/s40273-016-0426-8
Graham J, McBride D, Stull D, Halliday A, Alexopoulos ST, Balp MM, Griffiths M, Agirrezabal I, Zuberbier T, Brennan A. Cost utility of omalizumab compared with standard of care for the treatment of chronic spontaneous urticaria. Pharmacoeconomics. 2016 Aug;34(8):815-27. doi: 10.1007/s40273-016-0412-1
Earnshaw SR, Dennett SL. Integer/linear mathematical programming models: a tool for allocating healthcare resources. Pharmacoeconomics. 2003 Jan 1;21(12):839-51.